A Novel BERberine derivative for Malignant MESothelioma

Project Information

BERMES

Grant agreement ID: 829416

DOI

10.3030/829416

Project closed

EC signature date 10 October 2018

Start date 1 November 2018

End date 31 October 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 1 550 942,50

EU contribution

€ 1 085 659,75

Coordinated by

APPLIED RESEARCH USING OMIC SCIENCES SL
Spain

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

Project website

Project website that will be kept updated during the whole project life

Documents, reports (2)

Dissemination plan: Report the foreseen dissemination actions
Report on dissemination activities

Publications

Conference proceedings (1)

P121: Targeting Thymidylate Synthase mRNA with a Novel Berberine Derivative in Malignant Mesothelioma

Author(s): Plasencia C, Lombardi P, Garcia V, Jimenez A, Ciudad C
Published in: iMig 2021 Programe Book, Issue Bianually, 2021, Page(s) 245
Publisher: International Mesothelioma Interest Group

Non-peer reviewed articles (1)

Coping with Asbestos Legacy

Author(s): Biocon
Published in: European Biotechnology, Issue Spring Edition, Volume 18, 2019, Page(s) 77, ISSN 2364-2351
Publisher: Biocon AG

Intellectual Property Rights

Patent (1)

BENZOQUINOLIZINIUM SALT DERIVATIVES AS ANTICANCER AGENTS

Application/Publication number: 10 730174
Date: 2010-07-06
Applicant(s): APPLIED RESEARCH USING OMIC SCIENCES SL